ArticleThe Journal of clinical endocrinology and metabolism2026
Ovarian reserve and endothelial health in healthy reproductive-age women.
Article in The Journal of clinical endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
contextWhile the literature suggests women with diminished ovarian reserve may have increased metabolic risk, implications for long-term health are unknown.
objectiveThis work aimed to investigate the relationship between ovarian reserve markers at baseline with a subsequent measure of endothelial dysfunction, as a proxy for cardiovascular risk.
methodsThis prospective cohort study was conducted in a community-based setting. Participants included 322 individuals from the Ovarian Aging Study (OVA), a National Institutes of Health-funded study of ovarian aging (average age 35.4 years at the time of baseline ovarian reserve measurements, and age 45.1 years at the time of endothelial dysfunction measurement). This study investigated the association of ovarian reserve markers at baseline with a subsequent (average of 9.7 years) assessment of cardiovascular risk using the Endothelial and Peripheral Arterial Tone reactive hyperemia index (RHI) score of endothelial function. Secondary outcomes including the American Heart Association PREVENT score, metabolic syndrome, telomere length, and mitochondrial DNA were evaluated.
resultsRHI as a continuous outcome was significantly positively associated both with antimüllerian hormone (AMH) and antral follicle count (AFC) on fully adjusted models (AMH coefficient 0.052; 95% CI, 0.008-0.096; P = .02; AFC coefficient 0.017; 95% CI, 0.001-0.032; P = .04). For secondary outcomes, the only result that was statistically significant was the association of fully adjusted AFC with metabolic syndrome (odds ratio 0.92; 95% CI, 0.86-0.99; P = .02). A sensitivity analysis of the premenopausal cohort (N = 246) had similar findings.
conclusionIn this longitudinal cohort of women with normal ovarian aging, baseline ovarian reserve markers of AMH and AFC were positively associated with endothelial function as a continuous outcome. Baseline ovarian reserve markers were not related to most secondary outcomes of cellular aging and metabolic risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.